Objective. Regarding interactions between pro-inflammatory cytokines and bone metabolism in rheumatoid arthritis (RA), we investigated the relationship between the serum levels of interleukin (IL)-1b, IL-6, soluble interleukin-2 receptor (sIL-2r), C-reactive protein (CRP), the vitamin D metabolites 25-hydroxyvitamin D3 ( 25OHD 3 ) and 1,25
Systemic osteoporosis is a frequent and serious comtumour necrosis factor alpha ( TNF-a) and IL-6 have been shown to act on osteoblasts and osteoclasts in vitro plication of rheumatoid arthritis (RA). Various pathogenetic mechanisms, such as chronic glucocorticoid and in vivo, resulting in an increase of bone resorption [8] [9] [10] [11] [12] [13] [14] . This bone-resorptive effect of pro-inflammatory treatment and immobilization, contribute to systemic bone loss in this disease [1] . On the other hand, the cytokines may influence parathyroid hormone (PTH ) secretion and 1,25(OH ) 2 D 3 synthesis. Furthermore, chronic inflammation process itself has been shown to be an important risk factor in the development of because the vitamin D receptor is expressed on activated T cells [6, 7] , the activation state of T cells may be a systemic osteoporosis in RA [2] [3] [4] . However, the mediator mechanisms and the link between the local arthritic critical determinant of the 1,25(OH ) 2 D 3 serum level. Thus, interactions between secretion and metabolism of process and systemic bone loss are still unclear.
In a previous study, we observed a decrease in serum calcium-regulating hormones and pro-inflammatory cytokines certainly have a role in the regulation of bone levels of 1,25-dihydroxyvitamin D3 [1,25(OH ) 2 D 3 ] and an increase in parameters of bone resorption (pyridinoturnover in chronic inflammatory diseases in general and especially in RA. line and deoxypyridinoline-collagen cross-links) with increasing disease activity in an unselected group of RA Therefore, the purpose of our study was to investigate whether there are relationships between serum levels of patients [5] . Therefore, we suggested that a disease activity-dependent decrease in 1,25(OH ) 2 D 3 may be an pro-inflammatory cytokines, soluble markers of T-cell activation, calcium-regulating hormones and boneimportant mediator mechanism between local inflammation and systemic bone loss in RA. 1,25(OH ) 2 D 3 has turnover parameters in RA patients which may be of particular importance regarding the pathogenesis of immunomodulatory functions, including the suppression of activated T cells and the modulation of the secretion osteoporosis in RA. of pro-inflammatory cytokines [6, 7] . On the other hand, the pro-inflammatory cytokines interleukin-1 (IL-1), women without hormone replacement therapy were (Pyd/crea) and as the Dpyd/creatinine ratio (Dpyd/crea), respectively. included in our study. We investigated 74 postmenopausal women with RA aged between 49 and 80 yr Statistical analysis (mean 64.8 yr), and with a disease duration ranging from 6 months to 44 yr (mean 8.6 yr). All patients
The data were analysed statistically using the SPSS for fulfilled at least four of the 1987 revised ACR criteria Windows Statistical Program. For correlation analysis, for RA [15] . With respect to the renal synthesis of we used the Spearman correlation coefficient. To com-1,25(OH ) 2 D 3 , only patients with normal serum creatinpare the parameters of the various patient groups, the ine levels were included in the study.
Mann-Whitney U-test was used. Differences of P < 0.05 Fifty-one patients aged between 50 and 79 yr (mean were considered significant. 64.8 yr), and with a disease duration between 6 months and 44 yr (mean 9.1 yr), were receiving glucocorticoid treatment (5-15 mg prednisolone/day), whereas 23
Results patients aged between 49 and 80 yr (mean 64.9 yr), and
Influence of therapy on parameters of disease activity with a disease duration between 6 months and 39 yr including serum cytokine levels and parameters of bone (mean 7.4 yr), were not. None of the patients were turnover administered i.m., intra-articular or i.v. steroids during the last 3 months before investigation. Twenty women According to therapy at the time of investigation, the post-menopausal women with RA were divided into were receiving disease-modifying anti-rheumatic drugs (DMARDs) (11 methotrexate, four azathioprine, four four groups: patients receiving neither glucocorticoids nor DMARDs, patients with glucocorticoid treatment sulphasalazine and one hydroxychloroquine).
but without DMARDs, patients treated with glucocorLaboratory tests and analytical techniques ticoids and DMARDs and, as a subgroup of these, patients who received methotrexate (MTX ) ( Table 2 ). The following parameters were investigated in the sera of patients: IL-1b, IL-6, soluble interleukin-2 receptor
The ESR was lower in patients receiving glucocorticoids but no DMARDs (P < 0.05), in patients treated with (sIL-2r), C-reactive protein (CRP), erythrocyte sedimentation rate ( ESR), albumin, the vitamin D 3 glucocorticoids and DMARDs (P < 0.01), and in the subgroup with MTX therapy (P < 0.01) compared to metabolites 25-hydroxyvitamin D3 (25OHD 3
) and 1,25(OH ) 2 D 3 , intact PTH (iPTH ), bone alkaline phospatients receiving neither glucocorticoids nor DMARDs. Patients treated with MTX had a lower ESR (P < 0.05) phatase (bALP), osteocalcin (OC ), tartrate-resistant acid phosphatase ( TRAP), calcium (Ca), calcium corand a higher serum albumin level (P < 0.05) than those treated with glucocorticoids only. sIL-2r was signifirected for albumin (Ca-alb.), and phosphate (PO4). Fasting venous blood samples were drawn between 7 cantly lower in patients treated with glucocorticoids than in those receiving neither glucocorticoids nor and 9 a.m. For the determination of vitamin D metabolites, iPTH and cytokines, serum aliquots were frozen DMARDs (P < 0.01). In patients treated with glucocorticoids alone (P < 0.05) and in those receiving glucocorand stored at −70°C until analysed. The measuring procedure, producer and intra-assay/interassay coeffiticoids and DMARDs (P < 0.01), we found a higher bALP activity than in patients receiving neither glucocients of variation of calcium-regulating hormones, cytokines and cytokine receptors are listed in Table 1. corticoids nor DMARDs. The serum concentration of PO4 was slightly lower in patients treated with MTX Furthermore, the excretion of pyridinoline (Pyd) and deoxypyridinoline (Dpyd) cross-links, as well as the than in those receiving neither glucocorticoids nor DMARDs (P < 0.05). The other parameters of bone calcium/creatinine ratio (Ca/crea) in the morning urine and the daily urinary calcium excretion, were measured. turnover, especially serum levels of vitamin D metabolites and iPTH, and the markers of bone resorption Pyd and Dpyd were determined in urine by a reversedphase HPLC method, described in detail by Mü ller et al.
(Pyd/crea, Dpyd/crea and TRAP), were not different between the four groups. [16 ] , and expressed as the Pyd/creatinine ratio T 1. Measuring procedure, producer and intra-assay/interassay coefficients of variation of calcium-regulating hormones, cytokines and cytokine receptors T 2. Influence of therapy on serum cytokine levels, parameters of disease activity and of bone metabolism in post-menopausal women with RA (mean values and ..)
IL-1b (pg/ml ) 1.05 ± Correlation between parameters of disease activity, activity, serum albumin and cytokine levels in post-menopausal women serum albumin and cytokine levels (Table 3) with RA CRP correlated positively with ESR (P < 0.001), IL-6 ESR Albumin IL-1b IL-6 sIL-2r (P < 0.05) and sIL-2r (P < 0.01), and was negatively related to serum albumin (P < 0.05). ESR showed a (P < 0.01), whereas neither IL-1b nor IL-6 were related to sIL-2r. Furthermore, IL-6 was negatively related to ***P < 0.001; **P < 0.01; *P < 0.05.
serum albumin (P < 0.05).
Correlation between markers of disease activity and positive correlation with serum levels of Ca-alb. parameters of bone metabolism (P < 0.01) and PO4 (P < 0.05), and with the renal excretion of Pyd (P < 0.01) and Dpyd (P < 0.01). Correlations between serum levels of pro-inflammatory cytokines, conventional parameters of disease activity, Relationship between serum levels of calcium-regulating calcium-regulating hormones as well as bone turnover hormones and parameters of bone turnover (Table 5 ) parameters are shown in Table 4 . IL-6 correlated negatively with the renal excretion of Dpyd (P < 0.01), Serum levels of 25OHD 3 were not related to 1,25(OH ) 2 D 3 , iPTH and to the parameters of bone but showed no correlation with calcium-regulating hormones, serum calcium and phosphate, and markers formation and bone resorption. 1,25(OH ) 2 D 3 levels correlated positively with iPTH (P < 0.001) and bALP of bone formation. The serum level of sIL-2r was negatively related to 1,25(OH ) 2 D 3 (P < 0.01) and iPTH (P < 0.01), but showed no significant correlation with the parameters of bone resorption. Serum levels of iPTH (P < 0.05), but positively related to renal Pyd excretion (P < 0.05). IL-1b yielded no significant correlation with correlated negatively with serum levels of Ca-alb. (P < 0.001) and PO4 (P < 0.05), and positively with calcium-regulating hormones and bone turnover parameters. CRP correlated negatively with 1,25(OH ) 2 D 3 bALP (P < 0.05). (P < 0.01), iPTH (P < 0.01) and bALP (P < 0.01), and
Influence of age on serum cytokine levels and bone positively with serum levels of Ca-alb. (P < 0.01) and turnover parameters with the renal excretion of Pyd (P < 0.01) and Dpyd (P < 0.01). ESR had a negative correlation with Neither serum levels of IL-1b, IL-6, sIL-2r, CRP, ESR and albumin nor parameters of bone turnover, including 1,25(OH ) 2 D 3 (P < 0.01) and bALP (P < 0.01), but a and ESR) and the excretion of collagen cross-links (Pyd ***P < 0.001; **P < 0.01; *P < 0.05.
and Dpyd). Measurement of renal Pyd and Dpyd excretion is not suitable for differentiating between periarticular and systemic bone resorption. However, because correlation between systemic bone loss and urinary Pyd and Dpyd excretion has been shown in a prospective cartilage degradation and periarticular bone resorption induced by pro-inflammatory cytokines with bonestudy in early RA [3] , indicating that activation of osteoclasts is the dominant process leading to bone loss resorbing properties, such as IL-1b, TNF-a and IL-6, is a main feature of the inflammation process in RA [22] , in this situation. In our study group of post-menopausal women with the significant increase in both Pyd and Dpyd excretion with increasing disease activity is likely to be partly due RA, the renal excretion of Dpyd correlated positively with the serum level of IL-6, indicating that increased to joint destruction. Increased periarticular bone resorption in RA has been demonstrated by histomorphosecretion of IL-6 is of pathogenetic importance in the process of bone resorption in RA. This assumption is metric investigation [17, 18] , and the excretion of Pyd has been shown to correlate with disease activity, bone in agreement with other in vivo and in vitro findings in RA patients. An increase in osteoclastogenesis, and in loss at the femoral neck and with the degree of joint damage in RA [19] [20] [21] . On the other hand, various data the secretion of the pro-inflammatory cytokines IL-6 and IL-8, have been shown in the iliac crest bone from patients with RA and from animal models indicate that an augmented state of activation of monocytes/ marrow in patients with RA [26, 29] . Moreover, it has been demonstrated in vitro that monocytes and macromacrophages with an increased secretion of proinflammatory cytokines and an increase in osteoclastophages from RA patients are capable of differentiating into osteoclasts [27] , and that the osteoclastogenesis in genesis in the bone marrow may contribute to both local and systemic bone loss [23] [24] [25] [26] [27] [28] [29] . A significant the RA synovium is linked to IL-6 and the soluble IL-6 36 ] . Bone ALP, as a marker of osteosystem by the pro-inflammatory cytokines IL-1 and TNF-a is thought to play a critical role in periarticular blast function, was negatively correlated with disease activity and positively related to both iPTH and and systemic bone resorption in RA [23, 25, 28] . This assumption is supported by the positive correlation 1,25(OH ) 2 D 3 . PTH and 1,25(OH ) 2 D 3 are hormones with bone-resorptive, but also osteoanabolic effects, and between IL-1b and IL-6, and between IL-6 and urinary Dpyd excretion in our patients. The positive correlation 1,25(OH ) 2 D 3 induces the expression of alkaline phosphatase in osteoblasts [37] . Therefore, the decrease in of both IL-6 and renal Dpyd excretion with CRP and ESR indicates that bone resorption in our postiPTH and 1,25(OH ) 2 D 3 may contribute to a suppression of bone formation in RA patients with high disease menopausal women with RA is due to the inflammatory process rather than to oestrogen deficiency.
activity. Although our study group consists of postContrary to the markers of bone resorption, the serum levels of the two calcium-regulating hormones with menopausal women without hormone replacement therapy, the group is heterogeneous with respect to age bone-resorptive and osteoanabolic properties, i.e. 1,25(OH ) 2 D 3 and iPTH, showed a strong negative and therapy. Especially glucocorticoid treatment, but also DMARDs, could affect calcium-regulating horcorrelation with disease activity. The decrease in 1,25(OH ) 2 D 3 and iPTH with increasing disease activity mones and bone turnover [1] . However, with the exception of bALP, the serum levels of calcium-regulating may at least in part be induced by an increase in bone resorption and in free ionized serum calcium. This hormones and bone-turnover parameters were not influenced by therapy with glucocorticoids and/or with hypothesis is supported by the strong negative correlation between iPTH and serum calcium corrected for DMARDs. The lower levels of bone ALP in patients receiving neither glucocorticoids nor DMARDs may albumin, and the positive correlation between iPTH and 1,25(OH ) 2 D 3 . Ionized calcium was not measured in this result from a slightly higher disease activity in these patients in comparison with patients treated with glucostudy. However, an increase in ionized calcium in patients with high disease activity may be assumed corticoids and/or DMARDs. Pro-inflammatory cytokines inhibited by glucocorticoids and some DMARDs because of the positive correlation between disease activity and serum calcium corrected for albumin. Although [38, 39] have been shown to suppress the expression of ALP in human osteoblasts [9, 10] . Methotrexate has we did not find a significant negative correlation between IL-6 and iPTH, the activation of the IL-6 system been shown Other additional mechanisms may be of importance only modest effects on the results of the study. In summary, our data indicate that in postfor the decrease in 1,25(OH ) 2 D 3 with increasing disease activity. Although renal 1,25(OH ) 2 D 3 synthesis has been menopausal women suffering from RA with high disease activity, an increased periarticular and systemic bone shown to decrease with aging [32], an age-related decrease in 1,25(OH ) 2 D 3 serum levels has been excluded resorption is associated with an increased secretion of IL-6, and with a downregulation of PTH and in our patients. Interestingly, serum levels of 1,25(OH ) 2 D 3 in our RA patients showed a marked 1,25(OH ) 2 D 3 serum levels resulting in decreased bone formation. With respect to an interruption of these negative correlation with sIL-2r. sIL-2r is an accepted marker of T-cell activation. Not silent, however, actipostulated pathogenetic mechanisms, the suppression of bone resorption by bisphosphonates and the application vated T cells express the vitamin D receptor ( VDR), and 1,25(OH ) 2 D 3 is known to have suppressive effects of active vitamin D metabolites are of particular importance in the prevention of systemic osteoporosis in RA on Th1 cytokine production by inducing an inhibition of IL-12 secretion by monocytes/macrophages [33] .
patients with high disease activity. sIL-2r showed a significant positive correlation with disease activity in our RA patients. Therefore, an Acknowledgement synovial tissue of patients with RA has been shown to
